Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi

robot
Abstract generation in progress

Sino Biopharmaceutical announced that it has entered into an exclusive license agreement with Sanofi for the drug Rovadicitinib. The short news piece from Reuters provides no further details regarding the terms or implications of this agreement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)